Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma.

Baohong LuoYu SunQinru ZhanYuting LuoYu ChenTongze FuTiantian YangLijuan RenZhongpeng XieXiaohua SituBixia LiuKejing TangZun-Fu Ke

Published in: Clinical and translational medicine (2024)

Our findings identified TIGIT as a promising therapeutic target for LUAD. LUAD could benefit more from the combined therapy of IL-15 stimulation and TIGIT blockade.

Keyphrases

stem cells
mesenchymal stem cells
cell therapy
replacement therapy
smoking cessation